Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFM) Restructuring Costs (2023 - 2025)

Historic Restructuring Costs for Sunshine Biopharma (SBFM) over the last 5 years, with Q3 2025 value amounting to $614661.0.

  • Sunshine Biopharma's Restructuring Costs rose 1590.07% to $614661.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year increase of 1315.14%. This contributed to the annual value of $3.1 million for FY2024, which is 4516.86% up from last year.
  • According to the latest figures from Q3 2025, Sunshine Biopharma's Restructuring Costs is $614661.0, which was up 1590.07% from $806605.0 recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Restructuring Costs registered a high of $925878.0 during Q1 2025, and its lowest value of $530334.0 during Q3 2024.
  • Moreover, its 3-year median value for Restructuring Costs was $720297.0 (2023), whereas its average is $741389.1.
  • The largest annual percentage gain for Sunshine Biopharma's Restructuring Costs in the last 5 years was 2578.92% (2024), contrasted with its biggest fall of 255.06% (2024).
  • Over the past 3 years, Sunshine Biopharma's Restructuring Costs (Quarter) stood at $720297.0 in 2023, then grew by 25.79% to $906056.0 in 2024, then crashed by 32.16% to $614661.0 in 2025.
  • Its Restructuring Costs stands at $614661.0 for Q3 2025, versus $806605.0 for Q2 2025 and $925878.0 for Q1 2025.